Therapeutic effect of ticagrelor on acute ST elevation myocardial infarction and its influence on short-term prognosis
10.3969/j.issn.1008-0074.2017.01.20
- VernacularTitle:替格瑞洛治疗急性 ST 段抬高型心肌梗死的疗效及近期预后
- Author:
Jiayong HU
;
Haoyue YU
;
Zhaojun CHEN
;
Xiaofeng TANG
- Keywords:
Myocardial infarction;
Platelet aggregation inhibitors;
Prognosis;
Ticagrelor
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2017;26(1):74-77
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore therapeutic effect of ticagrelor on patients with acute ST elevation myocardial in‐farction (STEMI) and its influence on short‐term prognosis .Methods :A total of 180 STEMI patients undergoing e‐mergency percutaneous coronary intervention (PCI) were selected ,randomly divided into clopidogrel group (n=90) and ticagrelor group (n=90) .Clinical therapeutic effect was compared between two groups ;platelet function ,inci‐dence of major adverse cardiovascular events (MACE) ,adverse reactions and bleeding events were observed in two groups .Results:Total effective rate of ticagrelor group was significantly higher than that of clopidogrel group (93.4% vs .87.8% ,P=0.036);compared with clopidogrel group on 24h and 7d after operation ,there were signif‐icant reductions in platelet aggregation rate [24h :(62.1 ± 5.2)% vs . (56.5 ± 5.4)% ,7d:(47.3 ± 6.1)% vs . (38.7 ± 5.2)% ] and P2Y12 reaction unit [24h:(218.1 ± 12.3) U vs . (201.3 ± 11.1) U ,7d:(173.4 ± 11.8) U vs . (152.6 ± 12.6) U] in ticagrelor , P< 0.05 all;there were no significant difference in incidence rates of MACE ,adverse reactions and bleeding events between two groups , P>0. 05 all .Conclusion:Compared with clopi‐dogrel ,ticagrelor can better reduce platelet aggregation rate and improve clinical therapeutic effect without increas‐ing incidence of adverse reactions and bleeding events .
